CEFALONIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H18N4O5S2
Molecular Weight	458.511
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)CC4=CC=CS4)C3=O)C([O-])=O)C=C1

InChI

InChIKey=FMZXNVLFJHCSAF-DNVCBOLYSA-N

InChI=1S/C20H18N4O5S2/c21-17(26)11-3-5-23(6-4-11)9-12-10-31-19-15(18(27)24(19)16(12)20(28)29)22-14(25)8-13-2-1-7-30-13/h1-7,15,19H,8-10H2,(H3-,21,22,25,26,28,29)/t15-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H18N4O5S2
Molecular Weight	458.511
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_10996-224-001_04032014100940.pdf

Cefalonium is a 1st generation cephalosporin with a broad spectrum of actvity against Gram-positive and Gram-negative bacterias. The drug inhibits the bacterial cell wall synthesis by binding to penicillin binding proteins. Cefalonium is approved for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_10996-224-001_04032014100940.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 235 Sources: http://www.msd-animal-health.co.nz/products/cepravin/020_Product-Details.aspx	Curative		Approved 8583	CEPRAVIN Approved Use In conjunction with, proper management of the cow during drying-off and over the dry period, correct administration of Cepravin Dry Cow at drying off: (1) Reduces new infections at drying off and in the dry period; (2) Treats subclinical mastitis that may be present at drying off; (3) Helps reduce SCC's and mastitis in the subsequent lactation.

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP19A1 429 CYP2C19 2057	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 23.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 81.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 82.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 75.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 72.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 70.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 71.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 68 \| 70	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/21743#section=BioAssay-Results Page: 82.0

PubMed

Title	Date	PubMed
Development of a rapid multi-residue assay for detecting β-lactams using penicillin binding protein 2x*.	2013-02	23336133
[Determination of 9 cephalosporin drug residues in beef by ultra performance liquid chromatography-tandem mass spectrometry].	2009-07	19938495
Effect of an intramammary teat seal and dry cow antibiotic in relation to dry period length on postpartum mastitis.	2007-02	17235153

Patents

Sample Use Guides

In Vivo Use Guide

1 syringe (250 mg) per quarter immediately after final milking.

Route of Administration: Other

In Vitro Use Guide

The activity of cefalonium against different bacterial strains was measured. The MIC90 values were: 0.125 ug/ml for Staphylococcus aureus, 0.0156 ug/ml for Streptococcus agalactiae, 0.0078 ug/ml for Streptococcus dysgalactiae, 0.06 ug/ml for Streptococcus uberis, 0.125 ug/ml for Arcanobacterium pyogenes, 2 ug/ml for Escherichia coli and Klebsiella spp.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:40:09 GMT 2025` Edited by `admin` on `Wed Apr 02 08:40:09 GMT 2025`
Record UNII	K2P920217W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFALONIUM

Official Name

English

CEPHALONIUM

Preferred Name

English

NSC-759292

Code

English

3-(4-CARBAMOYLPYRIDYLMETHYL)-8-OXO-7-(A-(THIEN-2-YL)ACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Common Name

English

41071

Code

English

CEFALONIUM [JAN]

Common Name

English

CEFALONIUM [MART.]

Common Name

English

CEPHALONIUM [MI]

Common Name

English

cefalonium [INN]

Common Name

English

CEPHALONIUM [GREEN BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357